微RNAs 调节结肠直肠癌患者的生存率
Hadi Chavoshi1, Soghra Bornehdeli2, Milad Asadi3
1Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Advanced biomedical research
|December 11, 2023
概括
微RNA-203 (miR-203) 在结肠直肠癌 (CRC) 中是下调的,与幸存者的表达相反相关. 这表明miR-203可能在CRC进展中起到致癌作用,影响淋巴结转移.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 幸存是一种促进瘤细胞存活的关键蛋白质.
- 微RNAs (miRNAs) 的失调与结直肠癌 (CRC) 的病原发生有关.
- 了解miRNA的生存目标对于CRC研究至关重要.
研究的目的:
- 在伊朗结肠直肠癌 (CRC) 患者中分析针对生存的微RNA (miRNA).
- 研究特定miRNA与瘤和边缘组织中幸存者的表达之间的关系.
- 探索miR-203在CRC进展和转移中的潜在作用.
主要方法:
- 定量实时PCR被用于确定幸存者和特定miRNAs (miR-34a,miR-16,miR-150,miR-203a) 的转录水平.
- 对50名伊朗CRC患者的瘤和边缘组织进行了分析.
- 进行了统计相关性和比较分析,以评估表达水平和关系.
主要成果:
- 与边缘组织相比,在瘤组织中,幸存者的mRNA表达显著增加 (折叠变化=3.21,P=0.0029).
- miR-16和miR-203a在瘤样本中显示出显著的下调调节 (分别是折叠变化=0.28,P=0.003和折叠变化=0.36,P=0.014).
- 在miR-203a和幸存者表达之间观察到显著的反相关性 (rho = -0.81; P < 0.001).
- 在淋巴结转移的CRC患者中,观察到更高的生存和miR-203表达水平.
结论:
- miR-203可能在结直肠癌 (CRC) 中起着瘤基因的作用.
- 观察到miR-203的下调及其与幸存者的反相关性表明有调节作用.
- miR-203与淋巴结转移的关联表明它可能参与CRC进展.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


